Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10567359 | 0.89 | KMT2A (0.49) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL55285 | 0.86 | CA1 (0.44) | KMT2AALDH1A1MEN1CYP3A4CYP2C9 | |
| SCHEMBL5181113 | 0.85 | KMT2A (0.55) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL6098155 | 0.83 | KMT2A (0.58) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL8257058 | 0.81 | KMT2A (0.51) | KMT2AALDH1A1HCRTR2FBP1 | |
| SCHEMBL2612654 | 0.80 | KMT2A (0.58) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL3256506 | 0.80 | KMT2A (0.58) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL8663815 | 0.80 | HSD11B1 (0.38) | KMT2AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10642276 | 0.80 | FBP1 (0.51) | KMT2AALDH1A1HCRTR2FBP1MEN1 | |
| SCHEMBL7026797 | 0.79 | CA12 (0.48) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007063024-A2 | KERATIN-BINDING EFFECTOR MOLECULES CONTAINING REACTIVE DYES | BASF SE (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-4810706-A | ANTIHISTAMINES | RECHERCHE SYNTEX (FR) | 1989-03-07 | — | — | US | disclosed |
| EP-0227077-A1 | Piperazine derivatives of theophylline and theobromine | LABORATOIRES SYNTEX S.A. (FR) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | KRT18, KLK3, KLKB1 | KMT2A 2796/4885ALDH1A1 2661/4885HCRTR2 4772/4885 |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | KMT2A 1677/4885ALDH1A1 281/4885HCRTR2 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.